BioRender 图标

Oligodendrocyte (myelinating) 4

Oligodendrocyte (myelinating) 4 - Editable icon of An oligodendrocyte with two end foot process that stretch below its cell body
[{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090de1/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090de1/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090de2/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090de2/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090de3/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090de3/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090de4/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090de4/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090de5/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090de5/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090de6/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090de6/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090de7/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090de7/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090de8/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090de8/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090de9/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090de9/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090dea/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090dea/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090deb/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090deb/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090dec/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090dec/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090ded/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090ded/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090dee/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090dee/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090def/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090def/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090df0/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090df0/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090df1/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090df1/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090df2/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090df2/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090df3/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090df3/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090df4/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090df4/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090df5/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090df5/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090df6/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090df6/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090df7/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090df7/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090df8/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090df8/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090df9/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090df9/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090dfa/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090dfa/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090dfb/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090dfb/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090dfc/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090dfc/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090dfd/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090dfd/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090dfe/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090dfe/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090dff/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090dff/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e00/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e00/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e01/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e01/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e02/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e02/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e03/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e03/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e04/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e04/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e05/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e05/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e06/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e06/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e07/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e07/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e08/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e08/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e09/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e09/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e0a/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e0a/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e0b/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e0b/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e0c/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e0c/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e0d/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e0d/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e0e/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e0e/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e0f/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e0f/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e10/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e10/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e11/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e11/625727977a64f70028a7ace1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e1d72132fa9c244d090e12/625727977a64f70028a7ace1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e1d72132fa9c244d090e12/625727977a64f70028a7ace1.png"}]
使用此图标 – 免费
注册无需信用卡。

此图标可在 BioRender 中完全编辑

  • 添加文本、形状及其他图标
  • 搜索 50,000 多种科学准确的图标
  • 重新着色并重新排列每一个图标、线条和标签
  • 导出或分享以满足任何使用需求
Scientist Avatars

加入 400 多万名科学家 的行列,制作可直接用于发表的图表

从图标到成品图表,只需几分钟

  • 搜索 来自 50,000 多个科学准确、经同行评审的图标
  • 自定义 添加标签、形状和更多图标——一切皆可完全编辑
  • 导出 或与协作者分享您的图表
    ‍

图标不合适?探索更多内容。

搜索涵盖 30 多个生命科学领域的 50,000 多个图标。

search icon
arrow-right
neuroglia,axon,pns,peripheral nervous system,myelination,myelin,myelin sheath,oligodendrocyte,oligodendroglia,myelinating oligodendrocyte
查看更多

尝试使用同义词,或注册以在应用中请求图标。

图像类型

Oligodendrocyte (myelinating) 4 icon JPEG

Oligodendrocyte (myelinating) 4 icon PNG

Oligodendrocyte (myelinating) 4 icon SVG

Oligodendrocyte (myelinating) 4 icon GIF

BioRender 图标常见问题解答

How are scientists using the Oligodendrocyte (myelinating) 4 icon in their work?

BioRender users often use the Oligodendrocyte (myelinating) 4 icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Cell Types.

我可以在 BioRender 图表或科学插图中使用此图标吗?

Yes, the Oligodendrocyte (myelinating) 4 is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the Oligodendrocyte (myelinating) 4 icon customizable in BioRender?

Most icons in BioRender, including the Oligodendrocyte (myelinating) 4 icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

Can I export figures that include the Oligodendrocyte (myelinating) 4 icon for publication or presentations?

Yes, figures containing the Oligodendrocyte (myelinating) 4 icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

How do I cite BioRender if I use this icon?

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

Is the Oligodendrocyte (myelinating) 4 icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the Oligodendrocyte (myelinating) 4 icon — especially those focused on Cell Types. You can search BioRender’s template library or add this icon manually to any canvas.

什么是 BioRender?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this Oligodendrocyte (myelinating) 4 icon along with our library of more than 30,000 life science icons.

在 BioRender 中使用此图标

立即开始制作专业的科学图表
antibody elements3D Phospholipid illustration

正在寻找科学内容?

浏览超过 5 万个经同行评审、易于使用且免费的图标和模板。

立即寻找您的专属素材
x icon